AC Immune (ACIU) – What Are Researchers Saying About This Stock?

Shares of AC Immune (NASDAQ:ACIU) have received a consensus rating of “Moderate Buy” from the five research firms that are covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, three have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $7.50.

Several research analysts have recently weighed in on ACIU shares. HC Wainwright restated a “buy” rating on shares of AC Immune in a research note on Thursday, September 24th. BTIG Research reaffirmed a “buy” rating and set a $8.00 price objective on shares of AC Immune in a research report on Wednesday, September 23rd. Zacks Research upgraded AC Immune from a “hold” rating to a “strong-buy” rating in a report on Tuesday, September 29th. Finally, Weiss Ratings downgraded AC Immune from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, October 20th.

AC Immune Price Performance

Shares of NASDAQ ACIU opened at $2.42 on Monday. The firm has a market cap of $246.28 million, a P/E ratio of -4.48 and a beta of 1.56. AC Immune has a twelve month low of $2.10 and a twelve month high of $4.00. The company has a 50 day moving average of $2.65 and a 200 day moving average of $2.62.

AC Immune (NASDAQ:ACIU) last issued its earnings results on Thursday, August 6th. The company reported $0.03 EPS for the quarter, beating the consensus estimate of ($0.10) by $0.13. The business had revenue of $18.67 million for the quarter, compared to the consensus estimate of $9.59 million. AC Immune had a negative return on equity of 100.17% and a negative net margin of 245.32%. As a group, equities analysts expect that AC Immune will post -0.60 earnings per share for the current fiscal year.

Institutional Trading of AC Immune

A number of institutional investors have recently made changes to their positions in the stock. Arrowstreet Capital Limited Partnership grew its stake in shares of AC Immune by 8.0% in the first quarter. Arrowstreet Capital Limited Partnership now owns 405,658 shares of the company’s stock worth $1,116,000 after acquiring an additional 30,035 shares during the period. Dimensional Fund Advisors LP raised its holdings in shares of AC Immune by 82.8% during the first quarter. Dimensional Fund Advisors LP now owns 390,165 shares of the company’s stock valued at $1,071,000 after purchasing an additional 176,701 shares during the last quarter. Finally, AXQ Capital LP purchased a new position in shares of AC Immune during the second quarter valued at approximately $25,000. Hedge funds and other institutional investors own 51.36% of the company’s stock.

About AC Immune

AC Immune SA is a clinical-stage biopharmaceutical company headquartered in Lausanne, Switzerland, focused on developing treatments and diagnostic products for neurodegenerative diseases. Its research primarily addresses Alzheimer’s disease, Parkinson’s disease and related disorders by targeting proteins believed to contribute to disease progression, including amyloid and tau.

The company’s technology platforms include SupraAntigen, which supports the discovery of antibodies and vaccines, and Morphomer, which is used to identify small-molecule compounds that may prevent or modify the abnormal aggregation of disease-associated proteins.